Dr. Bach is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. He is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients.
Dr. Bach described a 100-fold increase in cancer drug prices since 1965 after adjusting for inflation, and that the cost of an additional year of life from a cancer treatment increases by $8,500 each year.
In 2012, he and other physicians at MSK drew attention to the high price of a newly approved cancer drug and announced his hospital’s unprecedented move not to offer it to patients because of its high price tag with no notable improved clinical outcomes. The drug price was later cut in half by the manufacturer.
Dr. Bach’s work in lung cancer screening has led to the development of several lung cancer screening guidelines and one of the first-ever risk-prediction models for this disease. He has also proposed a number of strategies for Medicare to link payment to the value of healthcare services delivered.
Dr. Bach has been inducted into the National Academy of Medicine, American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006.
Dr. Bach has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He has also written numerous healthcare-related op-eds and been featured in mainstream media outlets such as the New York Times, New York magazine, the Wall Street Journal, Forbes, NPR, and 60 Minutes. View a comprehensive list of media coverage of Dr. Bach and his work.
Dr. Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar. Dr. Bach has been a faculty member in MSK’s Department of Epidemiology and Biostatistics since 1998 and a Senior Scholar at the International Agency for Research on Cancer since 2008. In 2020, Dr. Bach co-founded EQRx, a biotechnology startup focused on developing affordable drugs. He currently serves an advisory role within the organization.
Disclosures for the past 3 years:
Speaking Fees: (2019) NYS Rheumatology Society, Oppenheimer & Co. Inc., Cello Health Group, Oncology Analytics, Alliance of Community Health Plans, Nephron Research, Morgan Stanley, JP Morgan | (2018) Mercer, Cello Health Group (formerly Defined Health), National Cancer Reporting Fellowship, Washington Post, Forbes, Foundation Medicine, Alliance Bernstein, Association for Value-Based Cancer Care, Venrock, United Rheumatology, American Osteopathic Association, National Institute for Health Care Management | (2017) ASHP, Gilead Pharmaceuticals, WebMD, Baylor Medical School, HDArsrch Foundation, Goldman Sachs, Academy of Physicians in Clinical Research, Politico, Mayo-Transform Conference, Defined Health, Ohio State University, Vizient, JMP Securities, Hematology Oncology Pharmacy Association
Consulting: EQRx, GRAIL | (2019) GRAIL | (2018) Foundation Medicine, Grail
Board of Directors: (2020) Oncology Analytics | (2019) Oncology Analytics
Funding: (2020) Arnold Ventures (formerly Laura and John Arnold Foundation), Kaiser Permanente, National Cancer Institute, Conquer Cancer Foundation, Canary Foundation